Unsafe
Dangerous Omission
Patient Risk:
Low
Summary
FDA label content is not present in the extracted claims; the evaluation indicates a dangerous omission by not assessing or citing safety-label sections.
Category Scores
Accurate Statements
Unsupported Statements
Contradictions
Important Omissions
Assessment of label safety sections (Boxed Warning, Contraindications, Dosing and Administration, Pregnancy/Lactation, Pediatric Use) was omitted.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No direct safety recommendations or patient-specific risk information provided; however, omission of safety-label content could lead to misinterpretation of risk.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Dangerous Omission
Primary Issue
No FDA-prescribing-information label sections cited; safety-critical labels not evaluated.
Suggested Improvement
Cite and assess key label sections (Boxed Warnings, Contraindications, Dosing, Pregnancy/Lactation, Pediatric Use) when auditing label alignment.